aka BI 456906
Open any panel for the full data
Survodutide is a dual glucagon/GLP-1 receptor agonist being developed by Boehringer Ingelheim for obesity and non-alcoholic steatohepatitis (NASH). The glucagon component may increase energy expenditure while GLP-1 reduces appetite.
Third-party creator videos and discussion, surfaced for research context. Amino Axiom does not endorse creator claims.
Survodutide
Obesity Doctor: What’s Coming After Ozempic? Inside the New Drug Survodutide
your GLP-1 results will stall without this one thing 👇 resistance training 💪 not walking not yoga not “staying active” lifting heavy thing
I need you to hear this 👇 if you’ve been told your whole life that you just need more discipline, more willpower, more motivation — that wa
true GLP-1 non-response is actually rare 🧬 clinical data suggests it’s only a small fraction of patients. so if your medication “stopped wo